<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774380</url>
  </required_header>
  <id_info>
    <org_study_id>D419QC00007</org_study_id>
    <secondary_id>2020-005537-32</secondary_id>
    <nct_id>NCT04774380</nct_id>
  </id_info>
  <brief_title>Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer</brief_title>
  <acronym>LUMINANCE</acronym>
  <official_title>A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin&#xD;
      or carboplatin) plus etoposide (EP) as first-line treatment in participants with&#xD;
      extensive-stage small-cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in North America, Europe and the United Kingdom.&#xD;
&#xD;
      In this single arm study participants will be treated with with durvalumab alone and&#xD;
      concurrently with platinum-based chemotherapy and etoposide during the study period until&#xD;
      radiological disease progression, unless there is clinical progression, unacceptable&#xD;
      toxicity, withdrawal of consent, or another discontinuation criterion is met, as per&#xD;
      investigator assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">March 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with incidence of Grade 3 and higher adverse events (AEs)</measure>
    <time_frame>Until disease progression (Approximately upto 2 Years)</time_frame>
    <description>Assessment of incidence of Grade 3 and higher adverse events to evaluate safety and tolerability profile of durvalumab + EP treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with incidence of Immune mediated adverse events (imAEs)</measure>
    <time_frame>Until disease progression (Approximately upto 2 Years)</time_frame>
    <description>Assessment of imAEs to evaluate safety and tolerability profile of durvalumab + EP treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From screening until disease progression (Approximately 2 Years)</time_frame>
    <description>Assessment of efficacy of durvalumab + EP treatment by evaluating PFS according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). The PFS is the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from Investigational medicinal product (IMP) or receives another anticancer therapy prior to progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From screening until disease progression (Approximately 2 Years)</time_frame>
    <description>Assessment of the efficacy of durvalumab + EP treatment by evaluating ORR according to RECIST 1.1. The ORR will be assessed based on Investigator-assessed response to treatment of complete response (CR) and partial response (PR), per RECIST1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From screening until disease progression (Approximately 2 Years)</time_frame>
    <description>Assessment of the efficacy of durvalumab + EP treatment by evaluating DoR according to RECIST 1.1. The DoR is time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants remaining in response, 12 months from the time of first documented objective response (DoR12)</measure>
    <time_frame>From screening until disease progression (Approximately 2 Years)</time_frame>
    <description>Assessment of the efficacy of durvalumab + EP treatment by evaluating DoR12 according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants alive and progression-free at 12 months from first date of treatment (PFS12)</measure>
    <time_frame>From screening until disease progression (Approximately 2 Years)</time_frame>
    <description>Assessment of the efficacy of durvalumab + EP treatment by evaluating PFS12 according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall (OS)</measure>
    <time_frame>From screening until death due to any cause (Approximately 2 Years)</time_frame>
    <description>Assessment of the efficacy of durvalumab + EP treatment by evaluating OS according to RECIST 1.1. The OS is the time from the first date of treatment until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants alive at 12 months from first date of treatment (OS12)</measure>
    <time_frame>From screening until disease progression (Approximately 2 Years)</time_frame>
    <description>Assessment of the efficacy of durvalumab + EP treatment by evaluating OS12 according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and serious adverse events</measure>
    <time_frame>From Cycle 1 (3 weeks [21 days]) until disease progression (Approximately 2 Years)</time_frame>
    <description>Assessment of adverse events and serious adverse events to evaluate safety and tolerability profile of durvalumab + EP treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events of special interests</measure>
    <time_frame>From Cycle 1 (3 weeks [21 days]) until disease progression (Approximately 2 Years)</time_frame>
    <description>Assessment of adverse events of special interests to evaluate safety and tolerability profile of durvalumab + EP treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Extensive-stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Durvalumab - (cisplatin or carboplatin) - Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive durvalumab 1500 mg administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w) starting on Week 0 for 4 to 6 cycles. Thereafter, durvalumab monotherapy will be continued q4w post-chemotherapy unless specific treatment discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Participants will receive durvalumab via IV infusion on Day 1 of each cycle.</description>
    <arm_group_label>Durvalumab - (cisplatin or carboplatin) - Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Participants will receive cisplatin via IV administration on Day 1 of each cycle.</description>
    <arm_group_label>Durvalumab - (cisplatin or carboplatin) - Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Participants will receive carboplatin via IV administration Day 1 of each cycle..</description>
    <arm_group_label>Durvalumab - (cisplatin or carboplatin) - Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.</description>
    <arm_group_label>Durvalumab - (cisplatin or carboplatin) - Etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically- or cytologically-documented ES-SCLC (stage IV [T any, N any, M1 a/b],&#xD;
             or with T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal&#xD;
             volume that is too large to be encompassed in a tolerable radiation plan (Brain&#xD;
             metastases; must be asymptomatic or treated and stable off steroids and&#xD;
             anticonvulsants for at least 1 month prior to study treatment)&#xD;
&#xD;
          -  Participants must be considered suitable to receive a platinum-based chemotherapy&#xD;
             regimen as 1st line treatment for the ES-SCLC. Chemotherapy must contain either&#xD;
             cisplatin or carboplatin in combination with etoposide&#xD;
&#xD;
          -  World Health Organization/ Eastern Cooperative Oncology Group performance status of 0&#xD;
             to 2 at enrollment Baseline computed tomography/ magnetic resonance imaging results of&#xD;
             the brain, chest and abdomen (including liver and adrenal glands) within 28 days prior&#xD;
             to the treatment initiation&#xD;
&#xD;
          -  No prior exposure to immune-mediated therapy including, but not limited to, other&#xD;
             anti- CTLA-4, anti-Programmed cell death-1 (PD-1), anti- Programmed cell death&#xD;
             ligand-1 (PD-L1), and anti-PD-L2 (anti-PD-L2) antibodies, excluding therapeutic&#xD;
             anticancer vaccines&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
          -  Body weight &gt; 30 kg&#xD;
&#xD;
          -  Evidence of post-menopausal status or negative urinary or serum pregnancy test for&#xD;
             female pre-menopausal participants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allogeneic organ transplantation&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders, systemic lupus&#xD;
             erythematosus, sarcoidosis syndrome, or wegener syndrome&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease,&#xD;
             serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirement,&#xD;
             substantially increase risk of incurring AEs or compromise the ability of the&#xD;
             participant to give written informed consent&#xD;
&#xD;
          -  History of another primary malignancy except for:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease ≥ 5&#xD;
                  years before the first dose of Investigational medicinal product (IMP) and of low&#xD;
                  potential risk for recurrence&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
          -  History of leptomeningeal carcinomatosis and active primary immunodeficiency&#xD;
&#xD;
          -  Active infection including tuberculosis, hepatitis B, hepatitis C, human&#xD;
             immunodeficiency virus&#xD;
&#xD;
          -  Any unresolved toxicity Common Terminology Criteria for Adverse Events Grade ≥ 2 from&#xD;
             previous anticancer therapy&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients&#xD;
&#xD;
          -  Received prior systemic therapy for ES-SCLC&#xD;
&#xD;
          -  Medical contraindication to platinum (cisplatin or carboplatin)-etoposide-based&#xD;
             chemotherapy&#xD;
&#xD;
          -  Any concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment.&#xD;
             Concurrent use of hormonal therapy for non-cancer-related conditions is acceptable&#xD;
&#xD;
          -  Planned consolidation chest radiation therapy. Radiation therapy outside of the chest&#xD;
             for palliative care is allowed but must be completed before first dose of the study&#xD;
             medication&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of in IMP&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to the first dose of IMP&#xD;
&#xD;
          -  Participants who have received prior anti-PD-1 or anti PD-L1&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product administered&#xD;
             in the last 4 weeks&#xD;
&#xD;
          -  Female participants who are pregnant or breastfeeding or male or female participants&#xD;
             of reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 90 days after the last dose of durvalumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panagyurishte</city>
        <zip>4500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burgas</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <zip>703 84</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen - Bory</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Immenstadt</city>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <zip>01120</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adapazari</city>
        <zip>54290</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamukkale</city>
        <zip>20070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Aggressive malignancy</keyword>
  <keyword>Programmed cell death ligand-1</keyword>
  <keyword>Platinum-based chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

